Date: 2016-03-16
Type of information: Nomination
Compound:
Company: Vedanta Biosciences (USA - MA)
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 16, 2016, Vedanta Biosciences, pioneering the development of a new class of therapies designed to modulate the human microbiome, announced the appointment of former Genzyme group vice president, Bruce L. Roberts, Ph.D., as Chief Scientific Officer. Dr. Roberts has 30 years of experience in biotechnology and pharmaceutical drug discovery and development. He most recently served as head of Neuro-Immunology and Immune-Mediated Disease Research at Sanofi Genzyme where he directed pre-clinical efforts resulting in the introduction of therapeutic antibodies, gene therapies, cell therapies and small molecules into multiple clinical trials for the treatment of cancer, multiple sclerosis and autoimmunity.
Financial terms:
Latest news:
